

ASX Release

10th August 2016

Further Canine Trials to be Initiated in Australia with MPL in Combination with Chemotherapy

*Veterinary Oncologist, Dr Angela Frimberger will continue to recruit
and treat suitable canine patients that fail standard therapy*

PharmAust Limited (“PharmAust” or “the Company”) (ASX: PAA) is pleased to announce that it has received further interest from veterinary oncologist Dr Angela Frimberger to continue evaluation of MPL (monepantel) either as monotherapy or in combination with chemotherapy in dogs that have failed standard veterinary care. In the only previous studies evaluating MPL in conjunction with chemotherapy (carboplatin), neither of the two dogs treated suffered any adverse events despite the fact they both had advanced cancers and few treatment options. PharmAust will provide capsules newly formulated by Juniper Pharma Services for evaluation by Dr Frimberger’s team.

PharmAust’s Executive Chairman Dr Roger Aston said “Combining chemotherapy with MPL in a target species is a critical component of our development strategy both in canines and humans, as chemotherapy is usually a first line treatment of cancer. Furthermore, previous studies in rodent models showed highly significant synergy between chemotherapy and MPL without apparent enhancement of side-effects.”

Principal investigator and dog cancer specialist, Dr Angela Frimberger, based at Veterinary Oncology Consultants Pty Ltd said “So far we have shown that MPL is safe and has biological activity in dogs; and we have given it with carboplatin in two dogs with late stage, resistant cancers without any enhancement of side effects. With the newly formulated capsules, we are delighted to now be able to offer the combination of MPL with other standard chemotherapeutics as well as carboplatin, for dogs with cancer where standard therapy either is not an option or has not been effective.”

PharmAust will report progress with canine recruitment both in Cambridge and Sydney and possibly other Australian sites as canine patients are recruited.

The US companion pet market sales (est. 2011) are in the region of US\$14 billion whilst cancer therapies are estimated at \$550 million with a price point of around \$1,500 per treatment. PharmAust’s Executive Chairman Dr Roger Aston said “As MPL is already approved for veterinary use by PharmAust’s partner, a major global corporation in the Animal Health Industry, we believe that if successful in this trial, MPL will be able to be approved quickly for the treatment of dog cancers following a further pivotal study”.

***References:**

2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.

<http://www.vet-dc.com/25.html> American pet products manufacturers association, Inc. 2011-2012 National pet owner’s survey

For further details please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Mr Robert Bishop
Executive Director
Tel: 0417 445 180
robertbishop@pharmaust.com